GlobalResearch and clinical trials
Experts publish 15 recommendations for diagnosis and care in isovaleric acidemia
An international group of experts reviewed published studies on isovaleric acidemia.
Inborn errors of metabolism
An inherited metabolic disease. The body cannot break down a building block called leucine. During an episode, a sweaty-feet odor, vomiting and weakness can occur.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
Orphanet has a guideline for emergency doctors for this disease (language: French, English). See on Orphanet
This page is translated from the Turkish original.
This disease is followed through the “Inborn errors of metabolism” group.
Leucine is a building block found in many proteins. The enzyme that breaks it down works poorly or not at all. Isovaleric acid and similar substances build up. This buildup can damage the brain and nervous system.
Severity ranges from no symptoms at all to severe illness. In about half of the babies found through screening, the course is very mild.
In many countries, it is found through expanded newborn screening. Blood and urine tests guide the diagnosis. The diagnosis is confirmed with a genetic test.
A low-protein diet that restricts leucine and a special formula are used. The doctor may recommend some nutritional supplements. On sick days, protein is reduced for a short time and sugary foods are given. A child who cannot eat may receive sugar into a vein in hospital. With treatment started before symptoms appear, development is often normal. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. When relatives marry, the chance that two carriers have children together is higher. Genetic counselling guides the family.
Source: MedlinePlus Genetics: Isovaleric acidemia · NORD: Isovaleric Acidemia
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
GlobalResearch and clinical trials
An international group of experts reviewed published studies on isovaleric acidemia.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
EUNew treatments and approvals
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy.
USANew treatments and approvals
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia.
EuropeResearch and clinical trials
A total of 58 patients from 34 centers in seven European countries were followed.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:33
No separate ICD-11 code; WHO classifies this disease under: 5C50.E0
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.